Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 6/20 | 0.53 |
| ▸ | COMT | P21964 | 4/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998847 | 0.92 | FTO (0.44) | FTOCOMTTPMTEGFRABCB1 | |
| SCHEMBL20100887 | 0.88 | FTO (0.52) | FTOCOMTTPMTEGFRABCB1 | |
| SCHEMBL20100886 | 0.88 | FTO (0.69) | FTOCOMTTPMTEGFRABCB1 | |
| SCHEMBL20100890 | 0.87 | TDP1 (0.45) | FTOCOMTTPMTEGFRABCB1 | |
| SCHEMBL20100878 | 0.83 | ALDH1A1 (0.48) | FTOCOMTTPMTABCB1ABCC1 | |
| SCHEMBL8471655 | 0.83 | TPMT (0.47) | FTOCOMTTPMTABCB1ABCC1 | |
| SCHEMBL4608763 | 0.83 | FTO (0.68) | FTOCOMTTPMTABCB1ABCC1 | |
| SCHEMBL4608767 | 0.83 | FTO (0.68) | FTOCOMTTPMTABCB1ABCC1 | |
| SCHEMBL4609816 | 0.83 | FTO (0.68) | FTOCOMTTPMTABCB1ABCC1 | |
| SCHEMBL20100872 | 0.82 | FTO (0.43) | FTOCOMTABCB1ABCC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922316-B | FTO inhibitors | 北京生命科学研究所 | 2022-04-08 | — | — | CN | disclosed |
| EP-3885337-A1 | FTO INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2021-09-29 | — | — | EP | disclosed |
| EP-3303283-B1 | FTO INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-20180118665-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118665-A1 | FTO Inhibitors | FTO, ALKBH3, ALKBH1 | FTO 1/4885COMT 9/4885TPMT 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.